Anthropic says Claude autonomously discovered a new enzyme system in the DNA of bacteriophages, somewhat similar to CRISPR, the first result from its new biolab

AI-powered research platforms can now autonomously discover novel biological systems and tools, potentially accelerating scientific breakthroughs.

Anthropic announced that its AI, Claude, has autonomously discovered a novel enzyme system in bacteriophage DNA, resembling CRISPR technology. This marks the first scientific output from Anthropic's new wet laboratory and demonstrates Claude's potential for scientific research. The AI processed 210 million tokens over 21 hours, with nearly 950 agents identifying an unusual pattern that led to the discovery. Scientists provided the initial prompt and conducted lab validation, confirming the existence of the previously uncharacterized enzyme system. While the exact function of this system is still under investigation, Anthropic aims to showcase Claude's capabilities and its research direction to the scientific community. This discovery is part of Anthropic's broader strategy to leverage AI in scientific exploration, including drug discovery, as the company prepares for its public offering.

This discovery highlights the growing intersection of AI and biological research, suggesting that AI models are becoming capable of not just analyzing data but actively identifying new scientific phenomena. Anthropic's approach of using numerous AI agents to sift through vast genomic datasets signifies a scalable method for uncovering biological mechanisms. Such advancements could dramatically shorten the timeline for new discoveries, moving beyond human-driven hypothesis generation to AI-led exploration of the unknown.

The successful application of Claude in discovering a new enzyme system positions Anthropic to attract top scientific talent and expand its influence in fields like drug development. It also signals a competitive shift among AI companies to prove their models' utility in tangible scientific applications, potentially leading to new investment and partnerships in the AI-for-science sector.